Total trials
61
Active
1
Phase 3
28
Total enrollment
11,405
Pipeline matrix
Showing 1 of 1 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| NT 201 | — | — | — | 7 |
Next readouts
- 2025-06-19
Top conditions
- Healthy7
- Subjective Tinnitus4
- Blepharospasm3
- Cervical Dystonia3
- Alzheimer's Disease3
- Cerebral Palsy3
- Glabellar Frown Lines3
- Nasolabial Folds2
Frequently asked questions about Merz Pharmaceuticals GmbH
- How many clinical trials does Merz Pharmaceuticals GmbH have on ClinicalTrials.gov?
- Merz Pharmaceuticals GmbH is listed as the lead sponsor on 61 clinical trials in ClinicalTrials.gov, 1 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Merz Pharmaceuticals GmbH's trials are in Phase 3?
- 28 of Merz Pharmaceuticals GmbH's trials are in Phase 3, spread across 1 active drug program.
- What therapeutic areas does Merz Pharmaceuticals GmbH focus on?
- Merz Pharmaceuticals GmbH's most-studied conditions on ClinicalTrials.gov are Healthy, Subjective Tinnitus, Blepharospasm, Cervical Dystonia, Alzheimer's Disease.
- When are Merz Pharmaceuticals GmbH's next clinical trial readouts?
- Merz Pharmaceuticals GmbH has 1 upcoming primary-completion readout tracked here; the soonest is “Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury”, expected around 2025-06-19.